JP2009541268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541268A5 JP2009541268A5 JP2009515885A JP2009515885A JP2009541268A5 JP 2009541268 A5 JP2009541268 A5 JP 2009541268A5 JP 2009515885 A JP2009515885 A JP 2009515885A JP 2009515885 A JP2009515885 A JP 2009515885A JP 2009541268 A5 JP2009541268 A5 JP 2009541268A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazin
- alkyl
- indol
- amino
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 75
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 23
- -1 aminocarbonylphenyl Chemical group 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 239000011780 sodium chloride Substances 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000000651 prodrug Chemical group 0.000 claims 9
- 229940002612 prodrugs Drugs 0.000 claims 9
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 150000001204 N-oxides Chemical group 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000005842 heteroatoms Chemical group 0.000 claims 4
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 230000003287 optical Effects 0.000 claims 4
- 206010006895 Cachexia Diseases 0.000 claims 3
- 208000004981 Coronary Disease Diseases 0.000 claims 3
- 206010012601 Diabetes mellitus Diseases 0.000 claims 3
- 206010058108 Dyslipidaemia Diseases 0.000 claims 3
- 208000001130 Gallstone Diseases 0.000 claims 3
- 208000009576 Hypercholesterolemia Diseases 0.000 claims 3
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 206010061227 Lipid metabolism disease Diseases 0.000 claims 3
- 101700001448 MAPK3 Proteins 0.000 claims 3
- 101710029928 MAPK4 Proteins 0.000 claims 3
- 101700087081 MKNK1 Proteins 0.000 claims 3
- 102100014833 MKNK1 Human genes 0.000 claims 3
- 101700062305 MKNK2 Proteins 0.000 claims 3
- 102100014832 MKNK2 Human genes 0.000 claims 3
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 3
- 208000000927 Sleep Apnea Syndrome Diseases 0.000 claims 3
- 206010040979 Sleep apnoea syndrome Diseases 0.000 claims 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 201000001883 cholelithiasis Diseases 0.000 claims 3
- 201000008739 coronary artery disease Diseases 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 235000014632 disordered eating Nutrition 0.000 claims 3
- 201000006180 eating disease Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 3
- 201000001421 hyperglycemia Diseases 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 230000004968 inflammatory condition Effects 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 3
- 201000002859 sleep apnea Diseases 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- PNZKKQWBSPXAPD-UHFFFAOYSA-N 4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 PNZKKQWBSPXAPD-UHFFFAOYSA-N 0.000 claims 2
- LHFZSYIZPPCJQA-UHFFFAOYSA-N [3-(dimethylamino)pyrrolidin-1-yl]-[4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1CCC(N(C)C)C1 LHFZSYIZPPCJQA-UHFFFAOYSA-N 0.000 claims 2
- VEFWZQFPBUSMBL-UHFFFAOYSA-N [4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-morpholin-4-ylmethanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1CCOCC1 VEFWZQFPBUSMBL-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- IPBNVTMTIKJPSK-UHFFFAOYSA-N (3-aminoazetidin-1-yl)-[4-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)N1CC(N)C1 IPBNVTMTIKJPSK-UHFFFAOYSA-N 0.000 claims 1
- NCJJBSPRMXVTIW-UHFFFAOYSA-N (4-ethylpiperazin-1-yl)-[4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C1CN(CC)CCN1C(=O)C(C=C1OC)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 NCJJBSPRMXVTIW-UHFFFAOYSA-N 0.000 claims 1
- JNQRUUBGEMDSNI-UHFFFAOYSA-N (4-ethylpiperazin-1-yl)-[6-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]pyridin-3-yl]methanone Chemical compound C1CN(CC)CCN1C(=O)C(C=N1)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 JNQRUUBGEMDSNI-UHFFFAOYSA-N 0.000 claims 1
- XITUAKFNJMJXQZ-UHFFFAOYSA-N (4-methyl-1,4-diazepan-1-yl)-[6-[[6-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazin-2-yl]amino]pyridin-3-yl]methanone Chemical compound C1CN(C)CCCN1C(=O)C(C=N1)=CC=C1NC1=CN=CC(C=2NC3=CC=NC=C3C=2)=N1 XITUAKFNJMJXQZ-UHFFFAOYSA-N 0.000 claims 1
- SCCCDOPYCXBGPY-UHFFFAOYSA-N (4-methylpiperazin-1-yl)-[4-[[6-(1H-pyrrolo[2,3-c]pyridin-2-yl)pyrazin-2-yl]amino]phenyl]methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=CN=CC(C=2NC3=CN=CC=C3C=2)=N1 SCCCDOPYCXBGPY-UHFFFAOYSA-N 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
- XCUZPVBDBASDCD-UHFFFAOYSA-N 2,9-diazaspiro[4.5]decan-2-yl-[4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N(C1)CCC21CCCNC2 XCUZPVBDBASDCD-UHFFFAOYSA-N 0.000 claims 1
- PHLZSOMVNDLFQN-UHFFFAOYSA-N 2-[2-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-5-(4-methylpiperazine-1-carbonyl)phenoxy]-N,N-dimethylacetamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OCC(=O)N(C)C)=CC=1C(=O)N1CCN(C)CC1 PHLZSOMVNDLFQN-UHFFFAOYSA-N 0.000 claims 1
- GMDXKZWRGGYIIL-UHFFFAOYSA-N 2-[6-[4-(4-methylpiperazine-1-carbonyl)anilino]pyrazin-2-yl]-1H-indole-5-carboxamide Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=CN=CC(C=2NC3=CC=C(C=C3C=2)C(N)=O)=N1 GMDXKZWRGGYIIL-UHFFFAOYSA-N 0.000 claims 1
- DPHUNMBXCBPBOC-UHFFFAOYSA-N 3-[[6-(1-benzofuran-2-yl)pyrazin-2-yl]amino]-4-methoxy-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C1=C(NC=2N=C(C=NC=2)C=2OC3=CC=CC=C3C=2)C(OC)=CC=C1C(=O)N(C)C1CCN(C)C1 DPHUNMBXCBPBOC-UHFFFAOYSA-N 0.000 claims 1
- ZHRBUSCAJPHBJY-UHFFFAOYSA-N 3-chloro-N-[2-(diethylamino)ethyl]-4-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]benzamide Chemical compound ClC1=CC(C(=O)NCCN(CC)CC)=CC=C1NC1=CN=CC(C=2NC3=CC=C(F)C=C3C=2)=N1 ZHRBUSCAJPHBJY-UHFFFAOYSA-N 0.000 claims 1
- ANESEZVJTLJYQN-UHFFFAOYSA-N 3-fluoro-4-[6-(6-fluoro-1H-indol-2-yl)pyrazin-2-yl]-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(C=2N=C(C=NC=2)C=2NC3=CC(F)=CC=C3C=2)C(F)=CC=1C(=O)N(C)C1CCN(C)C1 ANESEZVJTLJYQN-UHFFFAOYSA-N 0.000 claims 1
- PKUBWSRLUOHNPZ-UHFFFAOYSA-N 3-fluoro-5-[6-(6-fluoro-1H-indol-2-yl)pyrazin-2-yl]-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C(F)=CC(C=2N=C(C=NC=2)C=2NC3=CC(F)=CC=C3C=2)=CC=1C(=O)N(C)C1CCN(C)C1 PKUBWSRLUOHNPZ-UHFFFAOYSA-N 0.000 claims 1
- RZLKZEGKUUMPDQ-UHFFFAOYSA-N 3-methoxy-4-[[6-(4-methoxy-1H-indol-2-yl)pyrazin-2-yl]amino]-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC(OC)=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 RZLKZEGKUUMPDQ-UHFFFAOYSA-N 0.000 claims 1
- OVSTYTDVQDWUBE-UHFFFAOYSA-N 3-methoxy-4-[[6-(5-methoxy-1H-indol-2-yl)pyrazin-2-yl]amino]-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C2=CC(OC)=CC=C2NC=1C(N=1)=CN=CC=1NC(C(=C1)OC)=CC=C1C(=O)N(C)C1CCN(C)C1 OVSTYTDVQDWUBE-UHFFFAOYSA-N 0.000 claims 1
- UNUXUUBNCRXUMH-UHFFFAOYSA-N 3-methoxy-N-methyl-4-[[6-(5-methyl-1H-indol-2-yl)pyrazin-2-yl]amino]-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(C)C=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 UNUXUUBNCRXUMH-UHFFFAOYSA-N 0.000 claims 1
- XMTXOOYCGUDHQX-UHFFFAOYSA-N 3-methoxy-N-methyl-4-[[6-(6-methyl-1H-indol-2-yl)pyrazin-2-yl]amino]-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC(C)=CC=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 XMTXOOYCGUDHQX-UHFFFAOYSA-N 0.000 claims 1
- OGSUUHVBRCGZAU-UHFFFAOYSA-N 4-[5-amino-6-(1-benzofuran-2-yl)pyrazin-2-yl]-N-(2,3-dihydroxypropyl)benzamide Chemical compound N1=C(C=2OC3=CC=CC=C3C=2)C(N)=NC=C1C1=CC=C(C(=O)NCC(O)CO)C=C1 OGSUUHVBRCGZAU-UHFFFAOYSA-N 0.000 claims 1
- OGSUUHVBRCGZAU-INIZCTEOSA-N 4-[5-amino-6-(1-benzofuran-2-yl)pyrazin-2-yl]-N-[(2S)-2,3-dihydroxypropyl]benzamide Chemical compound N1=C(C=2OC3=CC=CC=C3C=2)C(N)=NC=C1C1=CC=C(C(=O)NC[C@H](O)CO)C=C1 OGSUUHVBRCGZAU-INIZCTEOSA-N 0.000 claims 1
- HJANIWAXHMBUSG-UHFFFAOYSA-N 4-[5-amino-6-(1-benzofuran-2-yl)pyrazin-2-yl]-N-[3-[bis(2-hydroxyethyl)amino]propyl]benzamide Chemical compound N1=C(C=2OC3=CC=CC=C3C=2)C(N)=NC=C1C1=CC=C(C(=O)NCCCN(CCO)CCO)C=C1 HJANIWAXHMBUSG-UHFFFAOYSA-N 0.000 claims 1
- LANXWFYAJDTUQO-UHFFFAOYSA-N 4-[5-amino-6-(1-benzofuran-2-yl)pyrazin-2-yl]-N-ethyl-N-(2-hydroxyethyl)benzamide Chemical compound C1=CC(C(=O)N(CCO)CC)=CC=C1C1=CN=C(N)C(C=2OC3=CC=CC=C3C=2)=N1 LANXWFYAJDTUQO-UHFFFAOYSA-N 0.000 claims 1
- FANHFMGLTLDNKK-UHFFFAOYSA-N 4-[[6-(1-benzofuran-2-yl)pyrazin-2-yl]amino]-3-methoxy-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2OC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 FANHFMGLTLDNKK-UHFFFAOYSA-N 0.000 claims 1
- YDYGKLHXQAFPOD-QGZVFWFLSA-N 4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-N-[(3R)-pyrrolidin-3-yl]benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N[C@@H]1CCNC1 YDYGKLHXQAFPOD-QGZVFWFLSA-N 0.000 claims 1
- YDYGKLHXQAFPOD-KRWDZBQOSA-N 4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-N-[(3S)-pyrrolidin-3-yl]benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N[C@H]1CCNC1 YDYGKLHXQAFPOD-KRWDZBQOSA-N 0.000 claims 1
- ZRZOSUIBWQOEGM-UHFFFAOYSA-N 4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-N-piperidin-3-ylbenzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)NC1CCCNC1 ZRZOSUIBWQOEGM-UHFFFAOYSA-N 0.000 claims 1
- CGPRHVRLWRCWJA-UHFFFAOYSA-N 4-[[6-(4-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC(F)=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 CGPRHVRLWRCWJA-UHFFFAOYSA-N 0.000 claims 1
- ZJPPAUXADIFCJC-UHFFFAOYSA-N 4-[[6-(5-chloro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(Cl)C=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 ZJPPAUXADIFCJC-UHFFFAOYSA-N 0.000 claims 1
- PLYJSWZGCPGSCQ-UHFFFAOYSA-N 4-[[6-(5-cyano-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(C=C3C=2)C#N)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 PLYJSWZGCPGSCQ-UHFFFAOYSA-N 0.000 claims 1
- NWLPGLSOMDEYCD-UHFFFAOYSA-N 4-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 NWLPGLSOMDEYCD-UHFFFAOYSA-N 0.000 claims 1
- GBTXJILKTQBTQO-UHFFFAOYSA-N 4-[[6-(6-chloro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC(Cl)=CC=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 GBTXJILKTQBTQO-UHFFFAOYSA-N 0.000 claims 1
- KFNNXOYZKPSREJ-UHFFFAOYSA-N 4-[[6-(6-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC(F)=CC=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 KFNNXOYZKPSREJ-UHFFFAOYSA-N 0.000 claims 1
- QDBWBNDBUKEGSC-UHFFFAOYSA-N 4-[[6-(7-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=C(F)C=CC=C3C=2)C(OC)=CC=1C(=O)N(C)C1CCN(C)C1 QDBWBNDBUKEGSC-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- XMYIYOJFJRSVMY-UHFFFAOYSA-N 6-[[6-(5-fluoro-1H-indol-2-yl)-1,4-dihydropyrazin-2-yl]imino]-3-(piperazine-1-carbonyl)cyclohexa-2,4-dien-1-one Chemical compound C=1C2=CC(F)=CC=C2NC=1C(N1)=CNC=C1N=C(C(C=1)=O)C=CC=1C(=O)N1CCNCC1 XMYIYOJFJRSVMY-UHFFFAOYSA-N 0.000 claims 1
- IUHWUPCYQXSYOL-UHFFFAOYSA-N C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=CN=CC(C=2NC3=CC=CC(O)=C3C=2)=N1 Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=CN=CC(C=2NC3=CC=CC(O)=C3C=2)=N1 IUHWUPCYQXSYOL-UHFFFAOYSA-N 0.000 claims 1
- PHEQIDUACUIYEG-UHFFFAOYSA-N N-(1,2-diethylpyrazolidin-4-yl)-4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxybenzamide Chemical compound C1N(CC)N(CC)CC1NC(=O)C(C=C1OC)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 PHEQIDUACUIYEG-UHFFFAOYSA-N 0.000 claims 1
- FQNVEWSIRAAFDY-UHFFFAOYSA-N N-(2,3-dihydroxypropyl)-4-[6-(1H-indol-2-yl)pyrazin-2-yl]benzamide Chemical compound C1=CC(C(=O)NCC(O)CO)=CC=C1C1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 FQNVEWSIRAAFDY-UHFFFAOYSA-N 0.000 claims 1
- UGOJBVXTCWYKAB-UHFFFAOYSA-N N-(2-hydroxyethyl)-4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCO)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 UGOJBVXTCWYKAB-UHFFFAOYSA-N 0.000 claims 1
- PSFHIIUZBHXNOR-UHFFFAOYSA-N N-(azetidin-3-yl)-4-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxybenzamide Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)NC1CNC1 PSFHIIUZBHXNOR-UHFFFAOYSA-N 0.000 claims 1
- FQNVEWSIRAAFDY-KRWDZBQOSA-N N-[(2S)-2,3-dihydroxypropyl]-4-[6-(1H-indol-2-yl)pyrazin-2-yl]benzamide Chemical compound C1=CC(C(=O)NC[C@H](O)CO)=CC=C1C1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 FQNVEWSIRAAFDY-KRWDZBQOSA-N 0.000 claims 1
- ULIMCJSUTRFRIF-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-fluoro-4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]benzamide Chemical compound C1=C(F)C(C(=O)NCCN(CC)CC)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 ULIMCJSUTRFRIF-UHFFFAOYSA-N 0.000 claims 1
- QFDRBXUQNMKNAH-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-4-[5-(1H-indol-2-yl)pyridin-3-yl]benzamide Chemical compound C1=CC(C(=O)NCCN(CC)CC)=CC=C1C1=CN=CC(C=2NC3=CC=CC=C3C=2)=C1 QFDRBXUQNMKNAH-UHFFFAOYSA-N 0.000 claims 1
- GLWMBNCIIMAGKE-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCN(CC)CC)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 GLWMBNCIIMAGKE-UHFFFAOYSA-N 0.000 claims 1
- TUNJGJAVESBYRU-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-4-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCN(CC)CC)=CC=C1NC1=CN=CC(C=2NC3=CC=C(F)C=C3C=2)=N1 TUNJGJAVESBYRU-UHFFFAOYSA-N 0.000 claims 1
- QEHZTXHMFSBBQW-UHFFFAOYSA-N N-[2-(dimethylamino)ethyl]-4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxy-N-methylbenzamide Chemical compound COC1=CC(C(=O)N(C)CCN(C)C)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 QEHZTXHMFSBBQW-UHFFFAOYSA-N 0.000 claims 1
- JWJMWQRKAQBITG-UHFFFAOYSA-N N-[3-(dimethylamino)propyl]-4-[6-(1H-indol-2-yl)pyrazin-2-yl]-N-methylbenzamide Chemical compound C1=CC(C(=O)N(C)CCCN(C)C)=CC=C1C1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 JWJMWQRKAQBITG-UHFFFAOYSA-N 0.000 claims 1
- VTNHHYGXQQBHGX-UHFFFAOYSA-N N-[3-(dimethylamino)propyl]-4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCCN(C)C)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 VTNHHYGXQQBHGX-UHFFFAOYSA-N 0.000 claims 1
- KRAFXUXYGUZYOZ-UHFFFAOYSA-N N-ethyl-N-(2-hydroxyethyl)-4-[6-(1H-indol-2-yl)pyrazin-2-yl]benzamide Chemical compound C1=CC(C(=O)N(CCO)CC)=CC=C1C1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 KRAFXUXYGUZYOZ-UHFFFAOYSA-N 0.000 claims 1
- RCOTZFFXLPZDMS-GOSISDBHSA-N [(3R)-3-(dimethylamino)pyrrolidin-1-yl]-[3-methoxy-4-[[6-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazin-2-yl]amino]phenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=NC=C3C=2)C(OC)=CC=1C(=O)N1CC[C@@H](N(C)C)C1 RCOTZFFXLPZDMS-GOSISDBHSA-N 0.000 claims 1
- AHAWPPZIBXCDSQ-HXUWFJFHSA-N [(3R)-3-(dimethylamino)pyrrolidin-1-yl]-[4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]phenyl]methanone Chemical compound C1[C@H](N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 AHAWPPZIBXCDSQ-HXUWFJFHSA-N 0.000 claims 1
- YSJOQWCLLYPLTQ-QGZVFWFLSA-N [(3R)-3-aminopyrrolidin-1-yl]-[4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1CC[C@@H](N)C1 YSJOQWCLLYPLTQ-QGZVFWFLSA-N 0.000 claims 1
- ONYIMVNCXQKHJT-QGZVFWFLSA-N [(3R)-3-aminopyrrolidin-1-yl]-[4-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)N1CC[C@@H](N)C1 ONYIMVNCXQKHJT-QGZVFWFLSA-N 0.000 claims 1
- XLWQOGPOLMFUFI-CALCHBBNSA-N [(3R,5S)-3,5-dimethylpiperazin-1-yl]-[4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1C[C@H](C)N[C@H](C)C1 XLWQOGPOLMFUFI-CALCHBBNSA-N 0.000 claims 1
- AHAWPPZIBXCDSQ-FQEVSTJZSA-N [(3S)-3-(dimethylamino)pyrrolidin-1-yl]-[4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]phenyl]methanone Chemical compound C1[C@@H](N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 AHAWPPZIBXCDSQ-FQEVSTJZSA-N 0.000 claims 1
- YSJOQWCLLYPLTQ-KRWDZBQOSA-N [(3S)-3-aminopyrrolidin-1-yl]-[4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1CC[C@H](N)C1 YSJOQWCLLYPLTQ-KRWDZBQOSA-N 0.000 claims 1
- MEQAZNGFRKGLQN-UHFFFAOYSA-N [2-chloro-4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound ClC1=CC(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)=CC=C1C(=O)N1CCNCC1 MEQAZNGFRKGLQN-UHFFFAOYSA-N 0.000 claims 1
- UOUOLDXTLRBHQM-UHFFFAOYSA-N [3-(2-ethoxyethoxy)-4-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OCCOCC)=CC=1C(=O)N1CCN(C)CC1 UOUOLDXTLRBHQM-UHFFFAOYSA-N 0.000 claims 1
- YVCKXRKFCLDWNJ-UHFFFAOYSA-N [3-[2-(dimethylamino)ethoxy]-4-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OCCN(C)C)=CC=1C(=O)N1CCN(C)CC1 YVCKXRKFCLDWNJ-UHFFFAOYSA-N 0.000 claims 1
- HMNYERMXRVUXNO-UHFFFAOYSA-N [3-chloro-4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]phenyl]-[4-[3-(dimethylamino)propyl]piperazin-1-yl]methanone Chemical compound C1CN(CCCN(C)C)CCN1C(=O)C(C=C1Cl)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 HMNYERMXRVUXNO-UHFFFAOYSA-N 0.000 claims 1
- ARBYDFNSZUAGKQ-UHFFFAOYSA-N [3-chloro-4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(Cl)=CC=1C(=O)N1CCNCC1 ARBYDFNSZUAGKQ-UHFFFAOYSA-N 0.000 claims 1
- TXTKMDKRXMPYGQ-UHFFFAOYSA-N [3-chloro-4-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound C=1C2=CC(F)=CC=C2NC=1C(N=1)=CN=CC=1NC(C(=C1)Cl)=CC=C1C(=O)N1CCNCC1 TXTKMDKRXMPYGQ-UHFFFAOYSA-N 0.000 claims 1
- OYWGCGGTQRVVRG-UHFFFAOYSA-N [3-fluoro-4-[6-(1H-indol-2-yl)pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(F)=C1 OYWGCGGTQRVVRG-UHFFFAOYSA-N 0.000 claims 1
- APJISWFEQVISDA-UHFFFAOYSA-N [3-fluoro-4-[6-(1H-indol-2-yl)pyrazin-2-yl]phenyl]-morpholin-4-ylmethanone Chemical compound C=1C=C(C=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(F)=CC=1C(=O)N1CCOCC1 APJISWFEQVISDA-UHFFFAOYSA-N 0.000 claims 1
- KUIRMWHHKSNSTJ-UHFFFAOYSA-N [3-methoxy-4-[[6-(6-methoxy-1H-indol-2-yl)pyrazin-2-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound N1C2=CC(OC)=CC=C2C=C1C(N=1)=CN=CC=1NC(C(=C1)OC)=CC=C1C(=O)N1CCNCC1 KUIRMWHHKSNSTJ-UHFFFAOYSA-N 0.000 claims 1
- LIZCVZCUXNDWID-UHFFFAOYSA-N [4-(2-hydroxyethyl)piperazin-1-yl]-[4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1CCN(CCO)CC1 LIZCVZCUXNDWID-UHFFFAOYSA-N 0.000 claims 1
- NQSJRTIBZZCLEA-UHFFFAOYSA-N [4-[2-(dimethylamino)ethyl]piperazin-1-yl]-[3-fluoro-5-[6-(6-fluoro-1H-indol-2-yl)pyrazin-2-yl]phenyl]methanone Chemical compound C1CN(CCN(C)C)CCN1C(=O)C1=CC(F)=CC(C=2N=C(C=NC=2)C=2NC3=CC(F)=CC=C3C=2)=C1 NQSJRTIBZZCLEA-UHFFFAOYSA-N 0.000 claims 1
- AMJCKPNZDXRZSB-UHFFFAOYSA-N [4-[3-(dimethylamino)propyl]piperazin-1-yl]-[4-[6-(1H-indol-2-yl)pyrazin-2-yl]phenyl]methanone Chemical compound C1CN(CCCN(C)C)CCN1C(=O)C1=CC=C(C=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C=C1 AMJCKPNZDXRZSB-UHFFFAOYSA-N 0.000 claims 1
- LJCCJXHEPSIOPN-UHFFFAOYSA-N [4-[3-(dimethylamino)propyl]piperazin-1-yl]-[4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-2-methoxyphenyl]methanone Chemical compound COC1=CC(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)=CC=C1C(=O)N1CCN(CCCN(C)C)CC1 LJCCJXHEPSIOPN-UHFFFAOYSA-N 0.000 claims 1
- STJFCFRPIAZTDO-UHFFFAOYSA-N [4-[3-(dimethylamino)propyl]piperazin-1-yl]-[4-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methylphenyl]methanone Chemical compound C1CN(CCCN(C)C)CCN1C(=O)C(C=C1C)=CC=C1NC1=CN=CC(C=2NC3=CC=C(F)C=C3C=2)=N1 STJFCFRPIAZTDO-UHFFFAOYSA-N 0.000 claims 1
- UGMCYWQTAFZSFE-UHFFFAOYSA-N [4-[5-(1H-indol-2-yl)pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C=C1 UGMCYWQTAFZSFE-UHFFFAOYSA-N 0.000 claims 1
- ZIVCXJIWLIRETL-UHFFFAOYSA-N [4-[5-(1H-indol-2-yl)pyridin-3-yl]phenyl]-morpholin-4-ylmethanone Chemical compound C=1C=C(C=2C=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C=CC=1C(=O)N1CCOCC1 ZIVCXJIWLIRETL-UHFFFAOYSA-N 0.000 claims 1
- DIGCBNOQNHBISN-UHFFFAOYSA-N [4-[5-amino-6-(1-benzofuran-2-yl)pyrazin-2-yl]-3-fluorophenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2N=C(C(N)=NC=2)C=2OC3=CC=CC=C3C=2)C(F)=C1 DIGCBNOQNHBISN-UHFFFAOYSA-N 0.000 claims 1
- NVMAZONXRCZIFD-UHFFFAOYSA-N [4-[5-amino-6-(1-benzofuran-2-yl)pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2N=C(C(N)=NC=2)C=2OC3=CC=CC=C3C=2)C=C1 NVMAZONXRCZIFD-UHFFFAOYSA-N 0.000 claims 1
- AMXQSVXXPXIFMM-UHFFFAOYSA-N [4-[5-amino-6-(1-benzofuran-2-yl)pyrazin-2-yl]phenyl]-morpholin-4-ylmethanone Chemical compound N1=C(C=2OC3=CC=CC=C3C=2)C(N)=NC=C1C(C=C1)=CC=C1C(=O)N1CCOCC1 AMXQSVXXPXIFMM-UHFFFAOYSA-N 0.000 claims 1
- FTZXELIUUGJIFS-UHFFFAOYSA-N [4-[5-amino-6-(1H-indol-2-yl)pyrazin-2-yl]-3-fluorophenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2N=C(C(N)=NC=2)C=2NC3=CC=CC=C3C=2)C(F)=C1 FTZXELIUUGJIFS-UHFFFAOYSA-N 0.000 claims 1
- NCJYQDIKWRZMGN-UHFFFAOYSA-N [4-[5-amino-6-(1H-indol-2-yl)pyrazin-2-yl]-3-fluorophenyl]-morpholin-4-ylmethanone Chemical compound N1=C(C=2NC3=CC=CC=C3C=2)C(N)=NC=C1C(C(=C1)F)=CC=C1C(=O)N1CCOCC1 NCJYQDIKWRZMGN-UHFFFAOYSA-N 0.000 claims 1
- PMUZRYBSGZBWRL-UHFFFAOYSA-N [4-[5-amino-6-(1H-indol-2-yl)pyrazin-2-yl]phenyl]-morpholin-4-ylmethanone Chemical compound N1=C(C=2NC3=CC=CC=C3C=2)C(N)=NC=C1C(C=C1)=CC=C1C(=O)N1CCOCC1 PMUZRYBSGZBWRL-UHFFFAOYSA-N 0.000 claims 1
- CUSBASMLBLPZHG-UHFFFAOYSA-N [4-[6-(1H-indol-2-yl)pyrazin-2-yl]phenyl]-morpholin-4-ylmethanone Chemical compound C=1C=C(C=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C=CC=1C(=O)N1CCOCC1 CUSBASMLBLPZHG-UHFFFAOYSA-N 0.000 claims 1
- IBEJZHNMZAVULE-UHFFFAOYSA-N [4-[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C=C1 IBEJZHNMZAVULE-UHFFFAOYSA-N 0.000 claims 1
- DGUSNOWIXMESGU-UHFFFAOYSA-N [4-[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]phenyl]-morpholin-4-ylmethanone Chemical compound C=1C2=CC(F)=CC=C2NC=1C(N=1)=CN=CC=1C(C=C1)=CC=C1C(=O)N1CCOCC1 DGUSNOWIXMESGU-UHFFFAOYSA-N 0.000 claims 1
- YCHVWRYIYRLCEF-UHFFFAOYSA-N [4-[6-(6-methyl-1H-indol-2-yl)pyrazin-2-yl]phenyl]-morpholin-4-ylmethanone Chemical compound N1C2=CC(C)=CC=C2C=C1C(N=1)=CN=CC=1C(C=C1)=CC=C1C(=O)N1CCOCC1 YCHVWRYIYRLCEF-UHFFFAOYSA-N 0.000 claims 1
- SGRLBYYCMNMZOL-UHFFFAOYSA-N [4-[[5-(1H-indol-2-yl)pyridin-3-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=C1 SGRLBYYCMNMZOL-UHFFFAOYSA-N 0.000 claims 1
- UVGHDHBQPQAISM-UHFFFAOYSA-N [4-[[5-(5-fluoro-1H-indol-2-yl)pyridin-3-yl]amino]phenyl]-(4-methyl-1,4-diazepan-1-yl)methanone Chemical compound C1CN(C)CCCN1C(=O)C(C=C1)=CC=C1NC1=CN=CC(C=2NC3=CC=C(F)C=C3C=2)=C1 UVGHDHBQPQAISM-UHFFFAOYSA-N 0.000 claims 1
- VYTBTGLIMYZDAJ-UHFFFAOYSA-N [4-[[5-(5-fluoro-1H-indol-2-yl)pyridin-3-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound C=1C2=CC(F)=CC=C2NC=1C(C=1)=CN=CC=1NC(C=C1)=CC=C1C(=O)N1CCNCC1 VYTBTGLIMYZDAJ-UHFFFAOYSA-N 0.000 claims 1
- JHLYSHJWXMJURV-UHFFFAOYSA-N [4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-(4-methyl-1,4-diazepan-1-yl)methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1CCCN(C)CC1 JHLYSHJWXMJURV-UHFFFAOYSA-N 0.000 claims 1
- VREHNJGXNKBGFR-UHFFFAOYSA-N [4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1CCN(C)CC1 VREHNJGXNKBGFR-UHFFFAOYSA-N 0.000 claims 1
- ICDZULFHPSAEPS-UHFFFAOYSA-N [4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C(OC)=CC=1C(=O)N1CCN(C(C)C)CC1 ICDZULFHPSAEPS-UHFFFAOYSA-N 0.000 claims 1
- ZUPXVNHSBSFWJC-QFIPXVFZSA-N [4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methanone Chemical class C([C@@H]1CCCN1C(=O)C=1C=C(C(=CC=1)NC=1N=C(C=NC=1)C=1NC2=CC=CC=C2C=1)OC)N1CCCC1 ZUPXVNHSBSFWJC-QFIPXVFZSA-N 0.000 claims 1
- HYNJDSXEWIFBRF-UHFFFAOYSA-N [4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-[4-(2-methoxyethyl)piperazin-1-yl]methanone Chemical compound C1CN(CCOC)CCN1C(=O)C(C=C1OC)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 HYNJDSXEWIFBRF-UHFFFAOYSA-N 0.000 claims 1
- QMKQGTZXNUZQKC-UHFFFAOYSA-N [4-[[6-(4-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-piperazin-1-ylmethanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC(F)=C3C=2)C(OC)=CC=1C(=O)N1CCNCC1 QMKQGTZXNUZQKC-UHFFFAOYSA-N 0.000 claims 1
- BOCABTCVUZPNCI-UHFFFAOYSA-N [4-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)N1CCN(C)CC1 BOCABTCVUZPNCI-UHFFFAOYSA-N 0.000 claims 1
- CMTPWEJEADPAFJ-OAHLLOKOSA-N [4-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-[(3R)-3-methylpiperazin-1-yl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)N1CCN[C@H](C)C1 CMTPWEJEADPAFJ-OAHLLOKOSA-N 0.000 claims 1
- CMTPWEJEADPAFJ-HNNXBMFYSA-N [4-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-3-methoxyphenyl]-[(3S)-3-methylpiperazin-1-yl]methanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)C(OC)=CC=1C(=O)N1CCN[C@@H](C)C1 CMTPWEJEADPAFJ-HNNXBMFYSA-N 0.000 claims 1
- BDAFYQPNCMBBGU-UHFFFAOYSA-N [5-[[5-(5-fluoro-1H-indol-2-yl)pyridin-3-yl]amino]pyridin-2-yl]-piperazin-1-ylmethanone Chemical compound C=1C2=CC(F)=CC=C2NC=1C(C=1)=CN=CC=1NC(C=N1)=CC=C1C(=O)N1CCNCC1 BDAFYQPNCMBBGU-UHFFFAOYSA-N 0.000 claims 1
- SGLFFQKYUVAORF-UHFFFAOYSA-N [5-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]pyridin-2-yl]-piperazin-1-ylmethanone Chemical compound C=1C2=CC(F)=CC=C2NC=1C(N=1)=CN=CC=1NC(C=N1)=CC=C1C(=O)N1CCNCC1 SGLFFQKYUVAORF-UHFFFAOYSA-N 0.000 claims 1
- LUMYNPZLRZBLQF-UHFFFAOYSA-N [5-chloro-4-[[6-(5-fluoro-1H-indol-2-yl)pyrazin-2-yl]amino]-2-methoxyphenyl]-piperazin-1-ylmethanone Chemical compound COC1=CC(NC=2N=C(C=NC=2)C=2NC3=CC=C(F)C=C3C=2)=C(Cl)C=C1C(=O)N1CCNCC1 LUMYNPZLRZBLQF-UHFFFAOYSA-N 0.000 claims 1
- VNHSDZLHPCFUJV-UHFFFAOYSA-N [6-[[5-(5-fluoro-1H-indol-2-yl)pyridin-3-yl]amino]pyridin-3-yl]-piperazin-1-ylmethanone Chemical compound C=1C2=CC(F)=CC=C2NC=1C(C=1)=CN=CC=1NC(N=C1)=CC=C1C(=O)N1CCNCC1 VNHSDZLHPCFUJV-UHFFFAOYSA-N 0.000 claims 1
- UONRFQNJFBKWEB-UHFFFAOYSA-N [6-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]pyridin-3-yl]-(4-methyl-1,4-diazepan-1-yl)methanone Chemical compound C1CN(C)CCCN1C(=O)C(C=N1)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 UONRFQNJFBKWEB-UHFFFAOYSA-N 0.000 claims 1
- FLHZZIIHBLTSNH-UHFFFAOYSA-N [6-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]pyridin-3-yl]-morpholin-4-ylmethanone Chemical compound C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)N=CC=1C(=O)N1CCOCC1 FLHZZIIHBLTSNH-UHFFFAOYSA-N 0.000 claims 1
- FVKBASVXAYEXPY-UHFFFAOYSA-N acetic acid;4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]benzamide Chemical compound CC(O)=O.C1=CC(C(=O)N)=CC=C1NC1=CN=CC(C=2NC3=CC=CC=C3C=2)=N1 FVKBASVXAYEXPY-UHFFFAOYSA-N 0.000 claims 1
- IRDCGQYTXLOSOM-UHFFFAOYSA-N acetic acid;[4-[[6-(1H-indol-2-yl)pyrazin-2-yl]amino]phenyl]-morpholin-4-ylmethanone Chemical compound CC(O)=O.C=1C=C(NC=2N=C(C=NC=2)C=2NC3=CC=CC=C3C=2)C=CC=1C(=O)N1CCOCC1 IRDCGQYTXLOSOM-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0601379 | 2006-06-22 | ||
| US85006706P | 2006-10-06 | 2006-10-06 | |
| PCT/EP2007/056213 WO2007147874A1 (en) | 2006-06-22 | 2007-06-21 | Pyridine and pyrazine derivatives as mnk kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009541268A JP2009541268A (ja) | 2009-11-26 |
| JP2009541268A5 true JP2009541268A5 (US07981874-20110719-C00313.png) | 2010-08-05 |
Family
ID=38566263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515885A Pending JP2009541268A (ja) | 2006-06-22 | 2007-06-21 | Ｍｎｋキナーゼ阻害剤としてのピリジンおよびピラジン誘導体 |
Country Status (12)
Families Citing this family (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2004656B1 (en) | 2006-04-07 | 2013-07-10 | Boehringer Ingelheim International GmbH | Thienopyrimidines having mnk1 /mnk2 inhibiting activity for pharmaceutical compositions |
| EP1889847A1 (en) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
| GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP2155689B1 (en) | 2007-05-31 | 2015-07-08 | Boehringer Ingelheim International GmbH | Ccr2 receptor antagonists and uses thereof |
| KR20100089090A (ko) | 2007-10-25 | 2010-08-11 | 아스트라제네카 아베 | 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체 |
| EP2219649A2 (en) * | 2007-11-22 | 2010-08-25 | Boehringer Ingelheim International Gmbh | Use of mnk inhibitors for the treatment of alzheimer's disease |
| WO2009099982A1 (en) * | 2008-02-04 | 2009-08-13 | Osi Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
| EA014100B1 (ru) * | 2008-02-21 | 2010-08-30 | Общество С Ограниченной Ответственностью "Валексфарм" | Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения |
| AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| CA2735361A1 (en) | 2008-08-26 | 2010-03-04 | Boehringer Ingelheim International Gmbh | Thienopyrimidines for pharmaceutical compositions |
| WO2010054398A1 (en) | 2008-11-10 | 2010-05-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2376485B1 (en) | 2008-12-19 | 2017-12-06 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
| EA020548B1 (ru) | 2008-12-19 | 2014-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл |
| US9260730B2 (en) | 2009-05-07 | 2016-02-16 | Aquatech Bioenergy LLC | Method and system for collecting ethanol from aquatic plants |
| ES2524829T3 (es) | 2009-12-17 | 2014-12-12 | Boehringer Ingelheim International Gmbh | Nuevos antagonistas del receptor CCR2 y usos de los mismos |
| AR080328A1 (es) | 2010-02-26 | 2012-03-28 | Boehringer Ingelheim Int | Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros |
| AU2011219758A1 (en) | 2010-02-26 | 2012-08-16 | Boehringer Ingelheim International Gmbh | 4 - [cycloalkyloxy (hetero) arylamino] thieno [2, 3 - d] pyrimidines having Mnkl/ Mnk2 inhibiting activity for pharmaceutical compositions |
| UY33241A (es) | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| MX2012013081A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
| JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| US8946218B2 (en) | 2010-05-12 | 2015-02-03 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| WO2011143425A2 (en) * | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| NZ603478A (en) | 2010-05-12 | 2014-09-26 | Vertex Pharma | 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
| EP2569298B1 (en) | 2010-05-12 | 2015-11-25 | Boehringer Ingelheim International GmbH | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| WO2011143423A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2569289A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
| JP5647339B2 (ja) | 2010-05-17 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２アンタゴニスト及びこれらの使用 |
| US9018212B2 (en) | 2010-05-25 | 2015-04-28 | Boehringer Ingelheim International Gmbh | Pyridazine carboxamides as CCR2 receptor antagonists |
| EP2576538B1 (en) | 2010-06-01 | 2015-10-28 | Boehringer Ingelheim International GmbH | New CCR2 antagonists |
| EP2585468A1 (en) | 2010-06-23 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| KR20140014205A (ko) | 2011-03-04 | 2014-02-05 | 렉시컨 파마슈티컬스 인코퍼레이티드 | Mst1 키나제 억제제 및 그의 사용 방법 |
| WO2012138938A1 (en) | 2011-04-05 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
| EP2710004A1 (en) * | 2011-05-17 | 2014-03-26 | Bayer Intellectual Property GmbH | Amino-substituted imidazopyridazines as mknk1 kinase inhibitors |
| JP6073868B2 (ja) * | 2011-06-01 | 2017-02-01 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換アミノイミダゾピリダジン |
| EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| EP2723747A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
| WO2013010839A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Novel and selective ccr2 antagonists |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| DK2755483T3 (en) | 2011-09-14 | 2019-03-11 | Samumed Llc | INDAZOL-3-CARBOXAMIDES AND ITS USE AS WNT / B-CATENIN SIGNAL INHIBITORS |
| ES2751741T3 (es) | 2011-09-30 | 2020-04-01 | Vertex Pharma | Procedimiento para fabricar compuestos útiles como inhibidores de la quinasa ATR |
| US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| MX2014003796A (es) | 2011-09-30 | 2015-01-16 | Vertex Pharma | Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr). |
| US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| MX2014003785A (es) | 2011-09-30 | 2014-07-24 | Vertex Phamaceuticals Inc | Tratamiento del cancer de pancreas y del cancer de pulmon de celulas no pequeñas con inhibidores de atr. |
| WO2013071085A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013071090A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| ME02535B (me) | 2012-02-17 | 2017-02-20 | Univ Cape Town | Antimalarijski agensi |
| GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| CA2869309C (en) | 2012-04-05 | 2021-02-09 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| WO2014055756A1 (en) | 2012-10-04 | 2014-04-10 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
| WO2014062604A1 (en) | 2012-10-16 | 2014-04-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2917185B1 (en) | 2012-11-09 | 2017-05-10 | Evotec International GmbH | Sulfoximine substituted quinazolines for pharmaceutical compositions |
| CA2891644A1 (en) | 2012-11-19 | 2014-05-22 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines |
| SG10201600149VA (en) | 2012-11-21 | 2016-02-26 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
| EP3808749B1 (en) | 2012-12-07 | 2023-03-08 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases |
| MX370487B (es) | 2013-01-08 | 2019-12-16 | Samumed Llc | Inhibidores de 3-(benzo-imidazol-2-il)-indazol de la senda de señalización de wnt y usos terapéuticos de los mismos. |
| EP2948447B1 (en) | 2013-01-23 | 2016-09-21 | Astrazeneca AB | Chemical compounds |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| CA2922657C (en) | 2013-08-30 | 2022-04-12 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| ES2693520T3 (es) | 2013-12-04 | 2018-12-12 | Evotec International Gmbh | Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas |
| HUE046727T2 (hu) | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
| WO2015091156A1 (en) | 2013-12-17 | 2015-06-25 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions |
| ES2749186T3 (es) | 2014-05-07 | 2020-03-19 | Evotec Int Gmbh | Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas |
| EP3152212B9 (en) | 2014-06-05 | 2020-05-27 | Vertex Pharmaceuticals Inc. | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
| JP6936007B2 (ja) | 2014-06-17 | 2021-09-15 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法 |
| TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
| WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| WO2016049565A1 (en) * | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| EP3197870B1 (en) | 2014-09-25 | 2020-08-19 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| WO2016140501A1 (en) * | 2015-03-04 | 2016-09-09 | Kainos Medicine, Inc. | Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors |
| AU2016245864C1 (en) | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法 |
| JP6917910B2 (ja) | 2015-07-02 | 2021-08-11 | セントレクシオン セラピューティクス コーポレイション | （４−（（３ｒ，４ｒ）−３−メトキシテトラヒドロ−ピラン−４−イルアミノ）ピペリジン−１−イル）（５−メチル−６−（（（２ｒ，６ｓ）−６−（ｐ−トリル）テトラヒドロ−２ｈ−ピラン−２−イル）メチルアミノ）ピリミジン−４イル）メタノンクエン酸塩 |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017024026A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10604512B2 (en) | 2015-08-03 | 2020-03-31 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof |
| WO2017024010A1 (en) * | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017024004A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| WO2017024025A1 (en) | 2015-08-03 | 2017-02-09 | Sunil Kumar Kc | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
| WO2017023988A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017024015A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017023984A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| US10231956B2 (en) | 2015-08-03 | 2019-03-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| WO2017023980A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| US10226448B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
| US10392383B2 (en) | 2015-08-03 | 2019-08-27 | Samumed, Llc | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017024021A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
| WO2017079519A1 (en) | 2015-11-06 | 2017-05-11 | Incyte Corporation | Heterocyclic compounds as pi3k-gamma inhibitors |
| JP6982747B2 (ja) | 2015-11-06 | 2021-12-17 | バイオスプライス セラピューティクス インコーポレイテッド | 変形性関節症の処置 |
| WO2017087528A1 (en) | 2015-11-16 | 2017-05-26 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| WO2017120194A1 (en) | 2016-01-05 | 2017-07-13 | Incyte Corporation | Pyridine and pyridimine compounds as pi3k-gamma inhibitors |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| CN109476660B (zh) | 2016-06-01 | 2023-04-04 | 拜斯丽治疗有限公司 | N-(5-(3-(7-(3-氟苯基)-3h-咪唑并[4,5-c]吡啶-2-基)-1h-吲唑-5-基)吡啶-3-基)-3-甲基丁酰胺的制备方法 |
| WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| CN110036010A (zh) | 2016-09-29 | 2019-07-19 | 亚瑞克西斯制药公司 | Kras g12c突变蛋白的抑制剂 |
| WO2018068017A1 (en) | 2016-10-07 | 2018-04-12 | Araxes Pharma Llc | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| CA3041291A1 (en) | 2016-10-21 | 2018-04-26 | Samumed, Llc | Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
| MA46696A (fr) | 2016-11-07 | 2019-09-11 | Samumed Llc | Formulations injectables à dose unique prêtes à l'emploi |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
| EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| KR20190117013A (ko) | 2017-02-14 | 2019-10-15 | 이펙터 테라퓨틱스, 인크. | 피페리딘-치환된 Mnk 억제제 및 그와 관련된 방법 |
| US10736897B2 (en) | 2017-05-25 | 2020-08-11 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
| KR20200010306A (ko) | 2017-05-25 | 2020-01-30 | 아락세스 파마 엘엘씨 | Kras의 공유적 억제제 |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| HUE056615T2 (hu) | 2017-10-18 | 2022-02-28 | Incyte Corp | Tercier hidroxicsoportokkal szubsztituált kondenzált imidazol-származékok mint PI3K-gamma inhibitorok |
| US11306079B2 (en) | 2017-12-21 | 2022-04-19 | Incyte Corporation | 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors |
| US11919902B2 (en) | 2017-12-22 | 2024-03-05 | Hibercell, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| LT3762368T (lt) | 2018-03-08 | 2022-06-10 | Incyte Corporation | Aminopirazindiolio junginiai, kaip pi3k-γ inhibitoriai |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| AU2019336675A1 (en) | 2018-09-05 | 2021-03-25 | Incyte Corporation | Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor |
| WO2020086713A1 (en) | 2018-10-24 | 2020-04-30 | Effector Therapeutics, Inc. | Crystalline forms of mnk inhibitors |
| AU2022324472A1 (en) * | 2021-08-05 | 2024-02-15 | 4E Therapeutics, Inc. | Methods of treating migraine with mnk inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5459266A (en) * | 1994-02-04 | 1995-10-17 | Hoechst Celanese Corporation | Substituted pyrazines |
| US5430123A (en) * | 1994-02-04 | 1995-07-04 | Hoechst Celanese Corporation | Polymer compositions containing substituted pyrazines |
| US5677459A (en) * | 1994-11-10 | 1997-10-14 | Sibia Neurosciences, Inc. | Methods for the preparation of modulators of acetylcholine receptors |
| US7122550B2 (en) * | 2002-05-23 | 2006-10-17 | Cytopia Pty Ltd | Protein kinase inhibitors |
| GB0428082D0 (en) * | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| US20100143341A1 (en) * | 2005-06-22 | 2010-06-10 | Develogen Aktiengesellschaft | Thienopyrimidines for pharmaceutical compositions |
-
2007
- 2007-06-21 BR BRPI0713328-6A patent/BRPI0713328A2/pt not_active IP Right Cessation
- 2007-06-21 CN CNA200780022963XA patent/CN101472912A/zh active Pending
- 2007-06-21 US US11/821,565 patent/US20080039450A1/en not_active Abandoned
- 2007-06-21 AT AT07786791T patent/ATE456565T1/de not_active IP Right Cessation
- 2007-06-21 RU RU2009101911/04A patent/RU2009101911A/ru not_active Application Discontinuation
- 2007-06-21 ES ES07786791T patent/ES2340093T3/es active Active
- 2007-06-21 WO PCT/EP2007/056213 patent/WO2007147874A1/en active Application Filing
- 2007-06-21 EP EP07786791A patent/EP2044051B1/en active Active
- 2007-06-21 AU AU2007263017A patent/AU2007263017A1/en not_active Abandoned
- 2007-06-21 CA CA002654358A patent/CA2654358A1/en not_active Abandoned
- 2007-06-21 JP JP2009515885A patent/JP2009541268A/ja active Pending
- 2007-06-21 DE DE602007004618T patent/DE602007004618D1/de active Active
